There are 4 papers on severe aplastic anemia in aging research: 3 observational studies in people, 1 in animals.
4 papers study it4 more mention it6 findings
See all 8 papers on severe aplastic anemia
- Humans3
- Animals1
Effects
5Cellular senescence
upin human cells1upin mice1
2 studies
Cellular senescence
upin human cells1upin mice1
Severe aplastic anemia increases cellular senescence in SAA MSCs vs controls.
Cellsin SAA MSCs vs controlsbone marrow mesenchymal stem cells
Severe aplastic anemia increases cellular senescence in mice (SAA mouse model induced by IFN-γ and busulfan) (75±11% vs 28±8% SA-β-gal positive cells).
AnimalsSAA mouse model induced by IFN-γ and busulfanbone marrow-derived mesenchymal stem cells
IGFBP1
upin human cells1
1 study
IGFBP1
upin human cells1
Severe aplastic anemia increases IGFBP1 in SAA MSCs vs controls.
Cellsin SAA MSCs vs controlsbone marrow mesenchymal stem cells
TXNIP
upin human cells1
1 study
TXNIP
upin human cells1
Severe aplastic anemia increases TXNIP in SAA MSCs vs controls.
Cellsin SAA MSCs vs controlsbone marrow mesenchymal stem cells
mTOR protein expression
upin mice1
1 study
mTOR protein expression
upin mice1
Severe aplastic anemia increases mTOR protein expression in mice (SAA mouse model induced by IFN-γ and busulfan).
AnimalsSAA mouse model induced by IFN-γ and busulfanbone marrow-derived mesenchymal stem cells
Cell proliferation
downin mice1
1 study
Cell proliferation
downin mice1
Severe aplastic anemia decreases cell proliferation in mice (SAA mouse model induced by IFN-γ and busulfan) (G0/G1 phase 77.461±1.567% vs 46.045±2.055%).
AnimalsSAA mouse model induced by IFN-γ and busulfanbone marrow-derived mesenchymal stem cells
Trial sponsors
Novartis Pharmaceuticals Corporation
Company2 trialsPhase 290 people
Company1 trialPhase 1/260 people
Peking University People's Hospital
3 trialsPhase 4206 people
Shanghai General Hospital, Shanghai Jiao Tong University School of Medicine
1 trialPhase 460 people
European Society for Blood and Marrow Transplantation
1 trialPhase 3202 people
1 trialPhase 353 people
National Heart, Lung, and Blood Institute
10 trialsPhase 2716 people
Masonic Cancer Center, University of Minnesota
2 trialsPhase 2108 people
Funding
1 grant since 2022National Heart, Lung, and Blood Institute$692K